Afrigen creates COVID vaccine using Moderna data
Afrigen Biologics has used the publicly available information relating to Moderna’s COVID-19 vaccine to manufacture its own version of the treatment, which could see testing by the end of this year.
Lupin and Sun settle Bromsite patent suit after ruling
Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Celgene, Dr Reddy's abandon cancer drug patent dispute
Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.
AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler
AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.
Virginia judge says court should deny class cert in Zetia antitrust suit
A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics.
Mylan gets green light to challenge Neurim melatonin patent
Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.
Mylan’s NHK-Fintiv challenge denied by SCOTUS
The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Groups urge Fed Circ to rehear Biogen patent case
Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.